We are a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. We plan to develop ABP-450 to address the estimated $2.2 billion global therapeutic botulinum toxin market, which is projected to grow […]

We are a blank check company recently incorporated as a Delaware corporation whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. To date, our efforts have […]

We currently intend to concentrate our efforts in identifying businesses which predominantly operate in Ibero-America and whose business strategy is aligned with energy transition and sustainability themes, in particular renewable energy. (Incorporated in the Cayman Islands)  (Note: Enphys Acquisition Corp. upsized its SPAC IPO at pricing on Oct. 5, 2021, to 30 million units, up […]

We intend to focus our efforts on businesses that manage, finance, operate, construct, control, own or support real estate or which derive a large component of revenue from real estate, construction or infrastructure-related activities. (Note: Crixus BH3 Acquisition Co. priced its SPAC IPO on Oct. 4, 2021, in line with the terms in its prospectus: […]

(Note: Gesher I Acquisition Corp. priced its SPAC IPO on Tuesday morning, Oct. 8, 2021, in line with the terms in its prospectus: 10 million units at $10 each to raise $100 million. The SPAC will start trading on Oct. 8th on the NASDAQ.) We intend to initially focus on target businesses located in Israel, […]

(Note: Rivian Automotive, Inc., an electric vehicle manufacturer, filed terms on Nov. 1, 2021, for its $8 billion IPO – the biggest deal of 2021. A $59.50 mid-point pricing would give Rivian a market valuation of nearly $52 billion – matching estimates reported last month by The Wall Street Journal and Reuters. The S-1/A filing […]

We are enabling deeper access to in vivo biology and driving durable and potentially transformational research on disease in a new era of advanced medicine. We believe our platform is the first to employ both proteomics, or the study of proteins and their functions, and single cell biology in an effort to fully characterize and link cellular […]

We will seek to identify, through the experience and expertise of our management team and board of directors, a biotech company that has demonstrated success and is primed to thrive in the rapidly evolving biotech industry. Our co-sponsor, Chardan Monterey, is affiliated with Chardan Capital Markets, LLC, or Chardan, an investment firm and a provider […]

We currently intend to concentrate our efforts in identifying high quality businesses that have recently undergone a restructuring. Our management team and Marblegate, an affiliate of our sponsor, have extensive experience investing in post-restructured companies. We believe that this experience makes us very well situated to identify, source, negotiate and execute a business combination at […]

We intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare and technology sectors, where our management team has extensive experience. Sectors we plan on exploring include, but are not limited to, technologically advanced […]